News

American Association of Individual Investors1d
Why Krystal Biotech, Inc.’s (KRYS) Stock Is Down 12.19%
Krystal Biotech, Inc.’s KRYS share price has dipped by 12.19%, which has investors questioning if this is right time to buy.
The Manila Times1d
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business ...
PETBOOK magazine on MSN3d
Originally a Hunting Dog! How the Golden Retriever Became a Popular Family Pet
It is a hunting dog, work partner, and family friend all in one. With its shiny golden coat and friendly expression, it ranks ...
Verywell Health on MSN6d
6 Benefits of MSM Supplements, According to Research
MSM is an anti-inflammatory dietary supplement sometimes used to reduce pain, improve skin health, relieve allergies, and ...
pharmaphorum2d
Rare disease drug from LEO's Timber felled by failed study
Timber's lead candidate TMB-001 for rare skin disease congenital ichthyosis failed to meet its efficacy objectives across the board in the ASCEND trial and will not support a planned regulatory ...
Zacks Investment Research on MSN1d
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
Krystal Biotech KRYS reported first-quarter 2025 earnings per share (EPS) of $1.20, which missed the Zacks Consensus Estimate ...
Hidradenitis Suppurativa Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Novartis Pharmaceuticals announced study is to establish the efficacy, safety, and tolerability of ...
gegen-hartz.de15h
Schwerbehinderung: Neue GdB Tabelle – alle Erkrankungen im Überblick
Wer mit gesundheitlichen Einschränkungen lebt, stellt sich häufig die Frage: Wie wird mein Grad der Behinderung (GdB) ...